Related Experiment Video
Updated: Jan 9, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment Regimen
Kenrick Ng1, Garima Priyadarshini2, Aaron Prendergast2
1Department of Medical Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
Clinical Genitourinary Cancer
|December 3, 2025
Summary
Salvage chemotherapy with the GAMMA regimen shows promise for relapsed germ cell tumors (GCTs). This oxaliplatin-based treatment achieved a 59% response rate in patients with poor-risk disease.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Relapsed germ cell tumors (GCTs) often require salvage chemotherapy for potential cure.
- Oxaliplatin-based regimens offer an alternative to cisplatin, potentially reducing toxicity and overcoming resistance.
- Early assessment of treatment response, such as via PET scans, may predict long-term outcomes in GCT patients.
Purpose of the Study:
- To evaluate the efficacy and safety of the GAMMA regimen (actinomycin D, methotrexate, paclitaxel, and oxaliplatin) as salvage chemotherapy for relapsed GCTs.
- To determine the objective response rate (ORR) as the primary endpoint.
- To assess progression-free survival (PFS), overall survival (OS), and toxicity, and to explore the predictive value of early PET scan response.
Main Methods:
- A single-arm, phase II clinical trial was conducted involving patients with GCTs who progressed after cisplatin-based chemotherapy.
- Participants received four cycles of the GAMMA regimen.
- Objective response rate, PFS, OS, and toxicity were evaluated. Survival analysis was stratified by International Prognostic Factors Study Group (IPFSG) risk criteria. PET CT response after one cycle was assessed for predictive value.
Main Results:
- Forty-four patients were treated, with a median age of 38; 70% had intermediate to very high-risk disease by IPFSG criteria.
- The objective response rate was 59.0% in the evaluable population.
- Median PFS was 9.7 months, and median OS was not reached. Notably, patients with high and very high-risk disease showed 2-year PFS rates of 33%. Early PET CT response did not predict PFS benefit.
Conclusions:
- The GAMMA regimen exhibits encouraging antitumor activity in relapsed GCT patients, including those with predominantly poor-risk disease.
- The findings support the potential role of this oxaliplatin-based regimen in salvage settings for GCTs.
- Further investigation may be warranted to optimize treatment strategies for high-risk GCT populations.
